Araujo-Castro M, Berrocal VR, Pascual-Corrales E (2020) Pituitary tumors: epidemiology and clinical presentation spectrum. Hormones 19:145–155. https://doi.org/10.1007/s42000-019-00168-8

Article  PubMed  Google Scholar 

Fleseriu M, Gurnell M, McCormack A et al (2025) Pituitary incidentaloma: a Pituitary Society international consensus guideline statement. Nat Rev Endocrinol 21:638–655. https://doi.org/10.1038/s41574-025-01134-8

Article  PubMed  Google Scholar 

Ezzat S, Asa SL, Couldwell WT et al (2004) The prevalence of pituitary adenomas: a systematic review. Cancer 101:613–619. https://doi.org/10.1002/cncr.20412

Article  PubMed  Google Scholar 

Molitch ME (2009) Pituitary incidentalomas. Best Pract Res Clin Endocrinol Metab 23:667–675. https://doi.org/10.1016/j.beem.2009.05.001

Article  CAS  PubMed  Google Scholar 

Daly AF, Beckers A (2020) The epidemiology of pituitary adenomas. Endocrinol Metab Clin North Am 49:347–355. https://doi.org/10.1016/j.ecl.2020.04.002

Article  PubMed  Google Scholar 

Fleseriu M, Varlamov EV, Hinojosa-Amaya JM, Langlois F, Melmed S (2023) An individualized approach to the management of Cushing disease. Nat Rev Endocrinol 19:581–599. https://doi.org/10.1038/s41574-023-00868-7

Article  PubMed  Google Scholar 

Burton T, Le Nestour E, Neary M, Ludlam WH (2016) Algorithm development and the clinical and economic burden of Cushing’s disease in a large US health plan database. Pituitary 19:167–174. https://doi.org/10.1007/s11102-015-0695-9

Article  PubMed  PubMed Central  Google Scholar 

Broder MS, Neary MP, Chang E, Ludlam WH (2015) Incremental healthcare resource utilization and costs in US patients with Cushing’s disease compared with diabetes mellitus and population controls. Pituitary 18:796–802. https://doi.org/10.1007/s11102-015-0654-5

Article  PubMed  Google Scholar 

Swearingen B, Wu N, Chen SY, Pulgar S, Biller BM (2011) Health care resource use and costs among patients with Cushing disease. Endocr Pract 17:681–690. https://doi.org/10.4158/EP10368.OR

Article  PubMed  Google Scholar 

Broder MS, Neary MP, Chang E, Cherepanov D, Ludlam WH (2015) Burden of illness, annual healthcare utilization, and costs associated with commercially insured patients with Cushing disease in the united States. Endocr Pract 21:77–86. https://doi.org/10.4158/EP14126.OR

Article  PubMed  Google Scholar 

Elbaum M, Kałużny M, Jawiarczyk-Przybyłowska A, Wojtczak B, Zembska A, Bolanowski M (2025) The costs of acromegaly management in Poland - analysis from one centre. Endokrynol Pol 76:86–93. https://doi.org/10.5603/ep.103200

Article  PubMed  Google Scholar 

Kamusheva M, Vandeva S, Mitov K et al (2020) New epidemiological, clinical and economic data for patients with acromegaly in Bulgaria. Front Public Health 8:147. https://doi.org/10.3389/fpubh.2020.00147

Article  PubMed  PubMed Central  Google Scholar 

Lesén E, Granfeldt D, Houchard A et al (2017) Comorbidities, treatment patterns and cost-of-illness of acromegaly in Sweden: a register-linkage population-based study. Eur J Endocrinol 176:203–212. https://doi.org/10.1530/EJE-16-0623

Article  PubMed  Google Scholar 

Roset M, Merino-Montero S, Luque-Ramírez M, Spanish group of the OASIS study et al (2012) Cost of clinical management of acromegaly in Spain. Clin Drug Investig 32:235–245. https://doi.org/10.2165/11599680-000000000-00000

Article  PubMed  Google Scholar 

Cocchiara F, Campana C, Nista F et al (2022) Evaluation of acromegaly treatment direct costs with respect to biochemical control and follow-up length. Pituitary 25:246–257. https://doi.org/10.1007/s11102-021-01193-w

Article  CAS  PubMed  Google Scholar 

Broder MS, Neary MP, Chang E, Cherepanov D, Katznelson L (2014) Treatments, complications, and healthcare utilization associated with acromegaly: a study in two large United States databases. Pituitary 17:333–341. https://doi.org/10.1007/s11102-013-0506-0

Article  CAS  PubMed  Google Scholar 

Ribeiro-Oliveira A, Brook RA, Munoz KA et al (2021) Burden of acromegaly in the United States: increased health services utilization, location of care, and costs of care. J Med Econ 24:432–439. https://doi.org/10.1080/13696998.2021.1898968

Article  PubMed  Google Scholar 

Placzek H, Xu Y, Mu Y, Begelman SM, Fisher M (2015) Clinical and economic burden of commercially insured patients with acromegaly in the United States: a retrospective analysis. J Manag Care Spec Pharm 21:1106–1112. https://doi.org/10.18553/jmcp.2015.21.12.1106

Article  PubMed  PubMed Central  Google Scholar 

Liu S, Adelman DT, Xu Y et al (2018) Patient-centered assessment on disease burden, quality of life, and treatment satisfaction associated with acromegaly. J Investig Med 66:653–660. https://doi.org/10.1136/jim-2017-000570

Article  PubMed  Google Scholar 

Bolin K, Gip C, Mörk AC, Lindgren B (2009) Diabetes, healthcare cost and loss of productivity in Sweden 1987 and 2005–a register-based approach. Diabet Med 26:928–934. https://doi.org/10.1111/j.1464-5491.2009.02786.x

Article  CAS  PubMed  Google Scholar 

Olsson DS, Svensson M, Labori F, De Geer A, Johannsson G (2023) Healthcare cost and survival in patients with non-functioning pituitary adenoma. Eur J Endocrinol 188:477–484. https://doi.org/10.1093/ejendo/lvad057

Article  CAS  PubMed  Google Scholar 

Lobatto DJ, van den Hout WB, Zamanipoor Najafabadi AH et al (2019) Healthcare utilization and costs among patients with non-functioning pituitary adenomas. Endocrine 64:330–340. https://doi.org/10.1007/s12020-019-01847-7

Article  CAS  PubMed  PubMed Central  Google Scholar 

van der Meulen M, Zamanipoor Najafabadi AH, Lobatto DJ et al (2021) Healthcare utilization and costs among prolactinoma patients: a cross-sectional study and analysis of determinants. Pituitary 24:79–95. https://doi.org/10.1007/s11102-020-01089-1

Article  PubMed  Google Scholar 

Basile M, Valentini I, Attanasio R et al (2024) A Pharmacoeconomic analysis from Italian guidelines for the management of prolactinomas. Glob Reg Health Technol Assess 11:1–16. https://doi.org/10.33393/grhta.2024.2601

Article  PubMed  PubMed Central  Google Scholar 

Sarikonda A, Quraishi D, Glener S et al (2025) Drivers of intraoperative costs for transsphenoidal endoscopic surgery for sellar lesions: a time-driven activity-based cost analysis. World Neurosurg 196:123792. https://doi.org/10.1016/j.wneu.2025.123792

Article  PubMed  Google Scholar 

Asemota AO, Ishii M, Brem H, Gallia GL (2019) Costs and their predictors in transsphenoidal pituitary surgery. Neurosurgery 85:695–707. https://doi.org/10.1093/neuros/nyy441

Article  PubMed  Google Scholar 

Little AS, Chapple K (2013) Predictors of resource utilization in transsphenoidal surgery for Cushing disease. J Neurosurg 119:504–511. https://doi.org/10.3171/2013.1.JNS121375

Article  PubMed  Google Scholar 

Dekkers AJ, de Vries F, Najafabadi AHZ et al (2022) Costs and its determinants in pituitary tumour surgery. Front Endocrinol 13:905019. https://doi.org/10.3389/fendo.2022.905019

Article  Google Scholar 

Lenders NF, McCormack AI, Ho KKY (2020) Management of endocrine disease: does gender matter in the management of acromegaly? Eur J Endocrinol 182:R67–R82. https://doi.org/10.1530/EJE-19-1023

Article  CAS  PubMed  Google Scholar 

Kreitschmann-Andermahr I, Siegel S, Kleist B et al (2016) Diagnosis and management of acromegaly: the patient’s perspective. Pituitary 19:268–276. https://doi.org/10.1007/s11102-015-0702-1

Article  PubMed  Google Scholar 

Dal J, Skov BG, Andersen M et al (2021) Sex differences in acromegaly at diagnosis: A nationwide cohort study and meta-analysis of the literature. Clin Endocrinol 94:625–635. https://doi.org/10.1111/cen.14392